{"url_path":"/sec/ueec/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1096938/0001477932-26-003228-index.html","accession_number":"0001477932-26-003228","cik":"0001096938","ticker":"UEEC","issuer_name":"United Health Products, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1096938/0001477932-26-003228-index.html","primary_entity_key":"0001096938","primary_entity_name":"United Health Products, Inc."},"word_count":419,"has_tables":true,"body_markdown":"ueec_10q.htm\n0001096938false--12-31Q120260.0013000000002586902532586902532586902530.00110000000000falsefalsefalsefalse169582000000000010969382026-01-012026-03-310001096938us-gaap:SubsequentEventMember2026-05-012026-05-140001096938us-gaap:SubsequentEventMemberueec:AnyMarketPurchaseAgreementMember2026-05-012026-05-140001096938us-gaap:SubsequentEventMemberueec:PromissoryNotePayableMember2026-05-012026-05-140001096938us-gaap:SubsequentEventMemberueec:PromissoryNotePayableMember2026-05-140001096938ueec:InstallmentThreeMember2026-01-012026-03-310001096938ueec:InstallmentTwoMember2026-01-012026-03-310001096938ueec:InstallmentOneMember2026-01-012026-03-310001096938us-gaap:WarrantMember2025-01-012025-12-310001096938us-gaap:WarrantMember2025-12-310001096938us-gaap:WarrantMember2024-01-012024-12-310001096938us-gaap:WarrantMember2024-12-3100010969382024-06-012024-06-200001096938srt:OfficerMember2025-01-012025-12-310001096938us-gaap:RestrictedStockUnitsRSUMember2025-12-310001096938us-gaap:RestrictedStockUnitsRSUMember2026-03-310001096938ueec:AnyMarketPurchaseAgreementMember2025-12-160001096938ueec:AnyMarketPurchaseAgreementMember2025-12-012025-12-160001096938ueec:BoardOfDirectorsMember2025-01-012025-03-310001096938ueec:WarrantsOneMember2026-01-012026-03-310001096938ueec:WarrantsOneMember2026-03-310001096938ueec:WarrantsMember2026-03-310001096938ueec:WarrantsMember2025-12-310001096938ueec:PromissoryNotePayableMember2026-03-310001096938ueec:PromissoryNotePayableMember2024-12-310001096938ueec:PromissoryNotePayableMember2026-01-012026-03-310001096938ueec:PromissoryNotePayableMember2024-12-160001096938ueec:PromissoryNotePayableMember2026-01-012026-01-090001096938ueec:PromissoryNotePayableMember2024-08-050001096938ueec:PromissoryNotePayableMember2026-01-090001096938us-gaap:ConvertibleDebtMember2022-01-012022-12-310001096938us-gaap:ConvertibleDebtMember2024-01-012024-12-310001096938us-gaap:ConvertibleDebtMember2026-03-310001096938us-gaap:ConvertibleDebtMember2025-12-3100010969382022-01-012022-12-3100010969382025-01-012025-12-310001096938ueec:TopMember2023-12-012023-12-150001096938us-gaap:ConvertibleDebtMember2025-01-012025-12-3100010969382024-01-012024-12-3100010969382022-12-310001096938ueec:OctoberSevenTwoZeraTwoFiveMember2026-01-012026-03-310001096938ueec:OctoberSevenTwoZeraTwoFiveMember2026-03-3100010969382023-12-012023-12-150001096938ueec:BottomMember2026-01-012026-03-310001096938ueec:TopMember2026-01-012026-03-310001096938ueec:RelatedPartiesMember2025-12-310001096938ueec:RelatedPartiesMember2026-03-310001096938ueec:RobertDenserMember2025-12-310001096938ueec:RobertDenserMember2026-03-310001096938srt:ChiefExecutiveOfficerMember2025-01-012025-12-310001096938srt:ChiefExecutiveOfficerMember2026-03-310001096938ueec:RobertDenserMember2022-12-310001096938ueec:AccruedliabilitiesRelatedPartiesMember2025-01-012025-12-310001096938ueec:AccruedliabilitiesRelatedPartiesMember2026-01-012026-03-310001096938ueec:TopsMember2023-12-012023-12-150001096938ueec:BottomMember2023-12-012023-12-150001096938ueec:OfficersAndDirectorsMember2022-01-012022-12-310001096938ueec:RobertDenserMember2022-01-012022-12-310001096938us-gaap:ConvertibleNotesPayableMember2026-01-012026-03-310001096938ueec:ConvertibleNotesPayableRelatedPartyMember2026-01-012026-03-310001096938us-gaap:ConvertibleNotesPayableMember2025-01-012025-03-310001096938ueec:ConvertibleNotesPayableRelatedPartyMember2025-01-012025-03-310001096938ueec:WarrantsMember2026-01-012026-03-310001096938ueec:WarrantsMember2025-01-012025-03-310001096938us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001096938us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001096938ueec:LavelTwoMember2026-03-310001096938ueec:LavelThreeMember2026-03-310001096938ueec:LavelOneMember2026-03-310001096938ueec:LavelTwoMember2025-12-310001096938ueec:LavelThreeMember2025-12-310001096938ueec:LavelOneMember2025-12-310001096938us-gaap:RetainedEarningsMember2026-03-310001096938us-gaap:AdditionalPaidInCapitalMember2026-03-310001096938us-gaap:CommonStockMember2026-03-310001096938us-gaap:RetainedEarningsMember2026-01-012026-03-310001096938us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001096938us-gaap:CommonStockMember2026-01-012026-03-310001096938us-gaap:RetainedEarningsMember2025-12-310001096938us-gaap:AdditionalPaidInCapitalMember2025-12-310001096938us-gaap:CommonStockMember2025-12-3100010969382025-03-310001096938us-gaap:RetainedEarningsMember2025-03-310001096938us-gaap:AdditionalPaidInCapitalMember2025-03-310001096938us-gaap:CommonStockMember2025-03-310001096938us-gaap:RetainedEarningsMember2025-01-012025-03-310001096938us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001096938us-gaap:CommonStockMember2025-01-012025-03-3100010969382024-12-310001096938us-gaap:RetainedEarningsMember2024-12-310001096938us-gaap:AdditionalPaidInCapitalMember2024-12-310001096938us-gaap:CommonStockMember2024-12-3100010969382025-01-012025-03-310001096938ueec:SeriesAConvertiblePreferredStockMember2026-03-310001096938ueec:SeriesAConvertiblePreferredStockMember2025-12-3100010969382025-12-3100010969382026-03-3100010969382026-05-15iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n**☒**\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the quarterly period ended **March 31, 2026**\n\n \n\n**☐**\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from ____________ to ____________\n\n \n\n**Commission file number: 000-27781**\n\n \n\n**UNITED HEALTH PRODUCTS, INC.**\n\n(Exact name of Company as specified in its charter)\n\n \n\n**Nevada**\n\n \n\n**84-1517723**\n\n(State or other jurisdiction\n\nof incorporation or organization)\n\n \n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n**520 Fellowship Road, Suite #D-406**\n\n**Mt. Laurel, NJ**\n\n \n\n**08054**\n\n(Address of Company’s principal executive offices)\n\n \n\n(Zip Code)\n\n \n\n**(475) 755-1005**\n\n(Company’s telephone number, including area code)\n\n \n\n**None**\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12 (b) of the Act: **None**\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐\n\n \n\nIndicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the 12 preceding months (or such shorter period that the registrant was required to submit such file). Yes ☒    No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated Filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\nEmerging growth company\n\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒\n\n \n\nThe number of shares issued and outstanding of the Registrant’s Common Stock, as of May 15, 2026 was 260,385,588.\n\n \n\n \n\n \n\n \n\n**UNITED HEALTH PRODUCTS, INC.**\n\n \n\n**FORM 10-Q QUARTERLY REPORT**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n \n\n**PAGE**\n\n \n\n**PART I. FINANCIAL INFORMATION**"}